NAGIOS: RODERIC FUNCIONANDO

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia

DSpace Repository

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia

dc.contributor.author	Lazzari, Lorenzo
dc.contributor.author	Balaguer-Roselló, Aitana
dc.contributor.author	Montoro, Juan
dc.contributor.author	Greco, Raffaella
dc.contributor.author	Hernani Morales, Rafael
dc.contributor.author	Lupo-Stanghellini, Maria Teresa
dc.contributor.author	Villalba, Marta
dc.contributor.author	Giglio, Fabio
dc.contributor.author	Facal, Ana
dc.contributor.author	Lorentino, Francesca
dc.contributor.author	Guerreiro, Manuel
dc.contributor.author	Bruno, Alessandro
dc.contributor.author	Pérez, Ariadna
dc.contributor.author	Xue, Elisabetta
dc.contributor.author	Clerici, Daniela
dc.contributor.author	Piemontese, Simona
dc.contributor.author	Piñana, José Luis
dc.contributor.author	Sanz, Miguel Ángel
dc.contributor.author	Solano Vercet, Carlos
dc.contributor.author	de la Rubia Comos, Javier
dc.contributor.author	Ciceri, Fabio
dc.contributor.author	Peccatori, Jacopo
dc.contributor.author	Sanz, Jaime
dc.date.accessioned	2022-09-06T07:48:40Z
dc.date.available	2022-09-06T07:48:40Z
dc.date.issued	2022
dc.identifier.uri	https://hdl.handle.net/10550/83733
dc.description.abstract	Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from HLA-matched sibling donor, 101 (42%) from HLA-matched and mismatched unrelated donor, and 64 (26%) from haploidentical donor. Except for neutrophil and platelet engraftment, which was slower in the haploidentical cohort, no significant differences were observed in major transplant outcomes according to donor type in univariate and multivariate analysis. GvHD prophylaxis with Sir-PTCy, with or without MMF, is safe and effective in patients with AML undergoing myeloablative allo-HSCT, resulting in low rates of transplant-related mortality, relapse/progression, and acute and chronic GvHD in all donor settings.
dc.language.iso	eng
dc.relation.ispartof	Bone Marrow Transplantation, 2022
dc.source	Lazzari, Lorenzo Balaguer-Roselló, Aitana Montoro, Juan Greco, Raffaella Hernani Morales, Rafael Lupo-Stanghellini, Maria Teresa Villalba, Marta Giglio, Fabio Facal, Ana Lorentino, Francesca Guerreiro, Manuel Bruno, Alessandro Pérez, Ariadna Xue, Elisabetta Clerici, Daniela Piemontese, Simona Piñana, Jose Luis Sanz, Miguel Ángel Solano Vercet, Carlos de la Rubia Comos, Javier Ciceri, Fabio Peccatori, Jacopo Sanz, Jaime 2022 Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia Bone Marrow Transplantation
dc.subject	Patologia
dc.title	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia
dc.type	journal article	es_ES
dc.date.updated	2022-09-06T07:48:40Z
dc.identifier.doi	https://doi.org/10.1038/s41409-022-01725-3
dc.identifier.idgrec	154548
dc.rights.accessRights	open access	es_ES